Navamedic reports slight increase of EBITDA for Q4 2016

Navamedic, a Norwegian, London-Listed pharmaceutical company, has reported Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of €0,6 million which represents small increase comparing to same period last year when company’s EBITDA was slightly under zero.

The ghighlight of the last quarter was the company’s expanding the distribution of angina prevention medicine, Imdur.

The company said that the Q4 2016 financial performance is a reflection of the Group’s strategy to build a stronger and more profitable business, driving necessary transformative actions and activities in current operations.